Anti-cd277 antibodies and uses thereof

Abstract

Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vγ9/VΩ T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.

1 . An isolated anti-CD277 antibody, comprising the 6 CDRs of mAb 103.2, said mAb103.2 being obtained from the hybridoma accessible under CNCM deposit number I-4403. 
     
     
         2 . The anti-CD277 antibody of  claim 1 , wherein said anti-CD277 antibody is a chimeric or humanized antibody. 
     
     
         3 . The anti-CD277 antibody of  claim 1 , wherein said anti-CD277 antibody is a murine antibody mAb103.2 as obtained from the hybridoma accessible under CNCM deposit number I-4403. 
     
     
         4 . The anti-CD277 antibody of  claim 1 , wherein said anti-CD277 antibody inhibits the cytolytic function, cytokine production and proliferation of Vγ9/Vδ2 T cells. 
     
     
         5 . A pharmaceutical composition comprising the anti-CD277 antibody of  claim 1 , in combination with one or more pharmaceutically acceptable excipients. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein said pharmaceutical composition is an injectable solution. 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein said pharmaceutical composition is formulated for intravenous or subcutaneous administration. 
     
     
         8 . A nucleic acid encoding at least the VH and VL domains of the anti-CD277 antibody of  claim 1 . 
     
     
         9 . The nucleic acid of  claim 8 , wherein said nucleic acid comprises DNA sequences encoding the CDRs of mAb 103.2, wherein said mAb 103.2 is obtained from the hybridoma accessible under CNCM deposit number I-4403. 
     
     
         10 . An expression vector comprising the nucleic acid of  claim 8 . 
     
     
         11 . A transformed host cell comprising the nucleic acid of  claim 8 , wherein said transformed host cell expresses said anti-CD277 antibody. 
     
     
         12 . A method for producing an anti-CD277 antibody, said method comprising:
 (i) culturing a transformed host cell comprising a nucleic acid encoding at least the VH and VL domains of an anti-CD277 antibody of  claim 1  under conditions suitable to allow expression of said anti-CD277 antibody,   (ii) recovering said expressed anti-CD277 antibody.   
     
     
         13 . A method for treating an autoimmune disease, transplantation rejection or a graft versus host disease in a subject in need thereof, wherein said method comprises the step of administering to said subject in need thereof a therapeutically effective amount of an anti-CD277 antibody which inhibits the cytolytic function, the cytokine production and the proliferation of Vγ9/Vδ2 T cells. 
     
     
         14 . The method of  claim 13 , wherein said anti-CD277 antibody is an isolated anti-CD277 antibody, comprising the 6 CDRs of mAb 103.2, said mAb103.2 being obtained from the hybridoma accessible under CNCM deposit number I-4403. 
     
     
         15 . A method for inhibiting the cytolytic function, the cytokine production and/or the proliferation of Vγ9/VΩ T cells in a subject, said method comprising administering an effective amount of an anti-CD277 antibody of  claim 1 .